Toward personalized therapy in AML: In vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML

Leukemia

Volumn 27, Issue 12, 2013, Pages 2379-2382

  Bernot, K M ^a,b   Siebenaler, R F ^a,b   Whitman, S P ^a,b   Zorko, N A ^a,b   Marcucci, G G ^a,b   Santhanam, R ^a,b   Ahmed, E H ^a,b   Ngangana, M ^a,b   McConnell, K K ^a,b   Nemer, J S ^a,b   Brook, D L ^a,b   Kulp, S K ^a,b   Chen, C S ^a,b   Frankhouser, D ^a,b   Yan, P ^a,b   Bundschuh, R ^b   Zhang, X ^a,b   Dorrance, A M ^a,b   Dickerson, K E ^a,b   Jarjoura, D ^a,b   Blum, W ^a,b   Marcucci, G ^a,b   Caligiuri, M A ^a,b   more..

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AR 42; DNA METHYLTRANSFERASE 1; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; METHYL CPG BINDING PROTEIN 2; MIXED LINEAGE LEUKEMIA PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; BONE MARROW; CANCER PROGNOSIS; DNA METHYLATION; EPIGENETICS; EX VIVO STUDY; FLOW CYTOMETRY; GENE MUTATION; IN VIVO STUDY; LETTER; LEUKOCYTE COUNT; NONHUMAN; PERSONALIZED MEDICINE; PHARMACODYNAMICS; PRIORITY JOURNAL; SPLEEN CELL; SPLEEN WEIGHT;

ANIMALS; EPIGENESIS, GENETIC; HUMANS; INDIVIDUALIZED MEDICINE; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, KNOCKOUT; MYELOID-LYMPHOID LEUKEMIA PROTEIN;

EID: 84890437337     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.147     Document Type: Letter

References (15)

1. Strout MP, Marcucci G, Bloomfield CD, Caligiuri MA. The partial tandem duplication of ALL1 (MLL) is consistently generated by Alu-mediated homologous recombination in acute myeloid leukemia. Proc Natl Acad Sci USA 1998; 95: 2390-2395.
2. Caligiuri MA, Strout MP, Lawrence D, Arthur DC, Baer MR, Yu F et al. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res 1998; 58: 55-59.
3. Dohner K, Tobis K, Ulrich R, Frohling S, Benner A, Schlenk RF et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 2002; 20: 3254-3261.
4. Schnittger S, Kinkelin U, Schoch C, Heinecke A, Haase D, Haferlach T et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia 2000; 14: 796-804.
5. Whitman SP, Ruppert AS, Marcucci G, Mrozek K, Paschka P, Langer C et al. Longterm disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. Blood 2007; 109: 5164-5167.
6. Whitman SP, Hackanson B, Liyanarachchi S, Liu S, Rush LJ, Maharry K et al. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood 2008; 112: 2013-2016.
7. Zorko NA, Bernot KM, Whitman SP, Siebenaler RF, Ahmed EH, Marcucci GG et al. Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias. Blood 2012; 120: 1130-1136.
8. Yan P, Frankhouser D, Murphy M, Tam HH, Rodriguez B, Curfman J et al. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood 2012; 120: 2466-2474.
9. Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001; 97: 1172-1179.
10. Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007; 25: 3884-3891.
11. Lu Q, Wang DS, Chen CS, Hu YD. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem 2005; 48: 5530-5535.
12. Lucas DM, Alinari L, West DA, Davis ME, Edwards RB, Johnson AJ et al. The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. PLoS One 2010; 5: e10941.
13. Mims A, AR Walker, Huang X, Sun J, Wang H, Santhanam R et al. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia 2012; 27: 871-878.
14. Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010; 107: 7473-7478.
15. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S et al. Phase 1/2 study of the combination of 5-aza-20-deoxycytidine with valproic acid in patients with leukemia. Blood 2006; 108: 3271-3279.